Agonist gating and isoflurane potentiation in the human gamma-aminobutyric acid type A receptor determined by the volume of a second transmembrane domain residue.
Gamma-aminobutyric acid type A (GABA(A) )receptors are targets for allosteric modulation by general anesthetics. Mutation of Ser270 within the second transmembrane domain of the GABA(A) receptor alpha subunit can ablate the modulation of the receptor by the anesthetic ether isoflurane. To investigate further the function of this critical amino acid residue, we made multiple amino acid substitutions at Ser270 and analyzed the concentration-dependent gating by GABA and regulation by isoflurane in each mutant receptor. There is a strong negative correlation between the EC(50) for GABA and the molecular volume of the amino acid residue at position 270. Replacement of Ser by large residues such as His and Trp produced a shift of the GABA concentration-response curve to the left, whereas replacement of Ser with Gly had the opposite effect. There also was a strong negative association between the molecular volume of the amino acid residue at 270 and the degree of enhancement of submaximal GABA responses by isoflurane. These results indicate the significance of the amino acid at position alpha270 in gating of the GABA(A) receptor. In addition, the data on isoflurane are consistent with the existence of a cavity of finite size in the region of alpha270 that may be filled by the anesthetic molecule or by the side chain of a larger residue at alpha270. The introduction of isoflurane, or of a large residue, into this cavity may stabilize the open state of the GABA(A) receptor relative to the closed state.
Koltchine
V V
VV
Department of Anesthesia and Critical Care, The University of Chicago, Chicago, Illinois, USA.
Finn
S E
SE
Jenkins
A
A
Nikolaeva
N
N
Lin
A
A
Harrison
N L
NL
D018685:Anesthetics, Inhalation / Q000494:pharmacology*; D002478:Cells, Cultured; D004594:Electrophysiology; D018755:GABA Agonists / Q000494:pharmacology*; D006801:Humans; D015640:Ion Channel Gating; D007530:Isoflurane / Q000494:pharmacology*; D016297:Mutagenesis, Site-Directed; D011487:Protein Conformation; D017434:Protein Structure, Tertiary; D011963:Receptors, GABA-A / Q000187:drug effects / Q000235:genetics / Q000378:metabolism*; D014162:Transfection
D018685:Anesthetics, Inhalation; D018755:GABA Agonists; D011963:Receptors, GABA-A; D007530:Isoflurane